Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.4.2 is shown on the page, replacing v3.4.1. The content related to the study remains unchanged.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no user-visible changes to page content were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedAdded glossary toggle options (Show glossary / Hide glossary) and minor metadata label changes (capitalization and revision/version update from v3.3.4 to v3.4.0) that do not affect the study's core content.SummaryDifference0.2%

- Check45 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no study data, eligibility criteria, or locations appear to be affected.SummaryDifference0.0%

- Check73 days agoChange DetectedLocations section updated with new site entries across multiple US states (Arizona, California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New York, Oregon, Texas, Washington) and international regions (Emilia-Romagna, Lazio, Lombardy, Barcelona); some previously listed locations were removed.SummaryDifference1.0%

- Check95 days agoChange DetectedA note that publications are automatically filled from PubMed was added, and the revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.